Ken Griffin Cara Therapeutics, Inc. Transaction History

Citadel Advisors LLC

  • $509 Billion
  • Q1 2024

Shares

22 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024
BUY
$0.6 - $1.65 $27,933 - $76,815
46,555 Added 118.8%
85,742 $63,000
Q3 2023

Nov 14, 2023
SELL
$1.67 - $3.33 $382,593 - $762,896
-229,098 Reduced 85.39%
39,187 $65,000
Q2 2023

Aug 14, 2023
SELL
$2.83 - $4.94 $606,429 - $1.06 Million
-214,286 Reduced 44.41%
268,285 $759,000
Q1 2023

May 15, 2023
BUY
$4.89 - $12.27 $1.86 Million - $4.66 Million
379,489 Added 368.14%
482,571 $2.37 Million
Q4 2022

Feb 14, 2023
BUY
$8.88 - $12.77 $69,379 - $99,772
7,813 Added 8.2%
103,082 $1.11 Million
Q3 2022

Nov 14, 2022
SELL
$8.24 - $12.56 $1.32 Million - $2.02 Million
-160,561 Reduced 62.76%
95,269 $892,000
Q2 2022

Aug 15, 2022
BUY
$7.45 - $13.84 $305,874 - $568,228
41,057 Added 19.12%
255,830 $2.34 Million
Q1 2022

May 16, 2022
BUY
$9.94 - $12.65 $2 Million - $2.54 Million
200,746 Added 1431.14%
214,773 $2.61 Million
Q4 2021

Feb 14, 2022
SELL
$11.99 - $18.14 $821,902 - $1.24 Million
-68,549 Reduced 83.01%
14,027 $170,000
Q3 2021

Nov 15, 2021
BUY
$11.55 - $16.06 $419,807 - $583,732
36,347 Added 78.62%
82,576 $1.28 Million
Q2 2021

Aug 16, 2021
SELL
$12.38 - $29.19 $2.11 Million - $4.99 Million
-170,813 Reduced 78.7%
46,229 $659,000
Q1 2021

May 17, 2021
BUY
$15.07 - $21.71 $375,664 - $541,186
24,928 Added 12.98%
217,042 $4.71 Million
Q4 2020

Feb 16, 2021
BUY
$12.72 - $16.16 $1.3 Million - $1.65 Million
101,926 Added 113.02%
192,114 $2.91 Million
Q3 2020

Nov 16, 2020
BUY
$12.34 - $17.92 $744,990 - $1.08 Million
60,372 Added 202.48%
90,188 $1.15 Million
Q2 2020

Aug 14, 2020
SELL
$12.39 - $17.33 $202,613 - $283,397
-16,353 Reduced 35.42%
29,816 $510,000
Q4 2019

Feb 14, 2020
SELL
$16.11 - $25.98 $6.1 Million - $9.83 Million
-378,467 Reduced 89.13%
46,169 $744,000
Q3 2019

Nov 14, 2019
BUY
$18.28 - $26.91 $1.74 Million - $2.56 Million
95,298 Added 28.94%
424,636 $7.76 Million
Q2 2019

Aug 14, 2019
BUY
$17.68 - $21.57 $212,089 - $258,753
11,996 Added 3.78%
329,338 $7.08 Million
Q1 2019

May 15, 2019
BUY
$14.41 - $19.64 $3.86 Million - $5.26 Million
267,837 Added 541.03%
317,342 $0
Q4 2018

Feb 14, 2019
BUY
$12.45 - $23.47 $114,465 - $215,783
9,194 Added 22.81%
49,505 $643,000
Q3 2018

Nov 13, 2018
SELL
$17.57 - $23.95 $654,658 - $892,377
-37,260 Reduced 48.03%
40,311 $0
Q3 2017

Nov 09, 2017
BUY
$12.6 - $16.34 $977,394 - $1.27 Million
77,571
77,571 $1.06 Million

Others Institutions Holding CARA

# of Institutions
102
Shares Held
21.5M
Call Options Held
50K
Put Options Held
0
View Full List

About Cara Therapeutics, Inc.

CARA Quotes by TradingView
  • Ticker CARA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 53,725,900
  • Market Cap $14M
  • Description
  • Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and...
More about CARA
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email